163 related articles for article (PubMed ID: 32798638)
1. Controlled loading of albumin-drug conjugates ex vivo for enhanced drug delivery and antitumor efficacy.
Liu X; Mohanty RP; Maier EY; Peng X; Wulfe S; Looney AP; Aung KL; Ghosh D
J Control Release; 2020 Dec; 328():1-12. PubMed ID: 32798638
[TBL] [Abstract][Full Text] [Related]
2. Therapeutic efficacy, pharmacokinetic profiles, and toxicological activities of humanized antibody-drug conjugate Zt/g4-MMAE targeting RON receptor tyrosine kinase for cancer therapy.
Yao HP; Feng L; Suthe SR; Chen LH; Weng TH; Hu CY; Jun ES; Wu ZG; Wang WL; Kim SC; Tong XM; Wang MH
J Immunother Cancer; 2019 Mar; 7(1):75. PubMed ID: 30871619
[TBL] [Abstract][Full Text] [Related]
3. Preclinical Efficacy of Anti-RON Antibody-Drug Conjugate Zt/g4-MMAE for Targeted Therapy of Pancreatic Cancer Overexpressing RON Receptor Tyrosine Kinase.
Yao HP; Feng L; Weng TH; Hu CY; Suthe SR; Mostofa AGM; Chen LH; Wu ZG; Wang WL; Wang MH
Mol Pharm; 2018 Aug; 15(8):3260-3271. PubMed ID: 29944378
[TBL] [Abstract][Full Text] [Related]
4. Cathepsin B Processing Is Required for the
Bernardim B; Conde J; Hakala T; Becher JB; Canzano M; Vasco AV; Knowles TPJ; Cameron J; Bernardes GJL
Bioconjug Chem; 2024 Feb; 35(2):132-139. PubMed ID: 38345213
[TBL] [Abstract][Full Text] [Related]
5. In Vitro and In Vivo Evaluation of Cysteine Rebridged Trastuzumab-MMAE Antibody Drug Conjugates with Defined Drug-to-Antibody Ratios.
Bryant P; Pabst M; Badescu G; Bird M; McDowell W; Jamieson E; Swierkosz J; Jurlewicz K; Tommasi R; Henseleit K; Sheng X; Camper N; Manin A; Kozakowska K; Peciak K; Laurine E; Grygorash R; Kyle A; Morris D; Parekh V; Abhilash A; Choi JW; Edwards J; Frigerio M; Baker MP; Godwin A
Mol Pharm; 2015 Jun; 12(6):1872-9. PubMed ID: 25894424
[TBL] [Abstract][Full Text] [Related]
6. hIMB1636-MMAE, a Novel TROP2-Targeting Antibody-Drug Conjugate Exerting Potent Antitumor Efficacy in Pancreatic Cancer.
Sun LP; Bai WQ; Zhou DD; Wu XF; Zhang LW; Cui AL; Xie ZH; Gao RJ; Zhen YS; Li ZR; Miao QF
J Med Chem; 2023 Nov; 66(21):14700-14715. PubMed ID: 37883180
[TBL] [Abstract][Full Text] [Related]
7. HER2-targeted antibody drug conjugates for ovarian cancer therapy.
Jiang J; Dong L; Wang L; Wang L; Zhang J; Chen F; Zhang X; Huang M; Li S; Ma W; Xu Q; Huang C; Fang J; Wang C
Eur J Pharm Sci; 2016 Oct; 93():274-86. PubMed ID: 27509865
[TBL] [Abstract][Full Text] [Related]
8. Synthesis, characterization, and targeted chemotherapy of SCT200-linker-monomethyl auristatin E conjugates.
Hu X; Jiang H; Bai W; Liu X; Miao Q; Wang L; Jin J; Cui A; Liu R; Li Z
Eur J Med Chem; 2021 Apr; 216():113297. PubMed ID: 33677351
[TBL] [Abstract][Full Text] [Related]
9. Antitumor effect of antitissue factor antibody-MMAE conjugate in human pancreatic tumor xenografts.
Koga Y; Manabe S; Aihara Y; Sato R; Tsumura R; Iwafuji H; Furuya F; Fuchigami H; Fujiwara Y; Hisada Y; Yamamoto Y; Yasunaga M; Matsumura Y
Int J Cancer; 2015 Sep; 137(6):1457-66. PubMed ID: 25704403
[TBL] [Abstract][Full Text] [Related]
10. A glypican-1-targeted antibody-drug conjugate exhibits potent tumor growth inhibition in glypican-1-positive pancreatic cancer and esophageal squamous cell carcinoma.
Munekage E; Serada S; Tsujii S; Yokota K; Kiuchi K; Tominaga K; Fujimoto M; Kanda M; Uemura S; Namikawa T; Nomura T; Murakami I; Hanazaki K; Naka T
Neoplasia; 2021 Sep; 23(9):939-950. PubMed ID: 34332450
[TBL] [Abstract][Full Text] [Related]
11. Old Drug, New Delivery Strategy: MMAE Repackaged.
Lahnif H; Grus T; Salvanou EA; Deligianni E; Stellas D; Bouziotis P; Rösch F
Int J Mol Sci; 2023 May; 24(10):. PubMed ID: 37239890
[TBL] [Abstract][Full Text] [Related]
12. Activating Autophagy Enhanced the Antitumor Effect of Antibody Drug Conjugates Rituximab-Monomethyl Auristatin E.
Wang Y; Zhang X; Fan J; Chen W; Luan J; Nan Y; Wang S; Chen Q; Zhang Y; Wu Y; Ju D
Front Immunol; 2018; 9():1799. PubMed ID: 30123222
[TBL] [Abstract][Full Text] [Related]
13. Characterization of Site-Specifically Conjugated Monomethyl Auristatin E- and Duocarmycin-Based Anti-PSMA Antibody-Drug Conjugates for Treatment of PSMA-Expressing Tumors.
Lütje S; Gerrits D; Molkenboer-Kuenen JD; Herrmann K; Fracasso G; Colombatti M; Boerman OC; Heskamp S
J Nucl Med; 2018 Mar; 59(3):494-501. PubMed ID: 29146698
[TBL] [Abstract][Full Text] [Related]
14. Bivalent EGFR-Targeting DARPin-MMAE Conjugates.
Karsten L; Janson N; Le Joncour V; Alam S; Müller B; Tanjore Ramanathan J; Laakkonen P; Sewald N; Müller KM
Int J Mol Sci; 2022 Feb; 23(5):. PubMed ID: 35269611
[TBL] [Abstract][Full Text] [Related]
15. In vivo drug-linker stability of an anti-CD30 dipeptide-linked auristatin immunoconjugate.
Sanderson RJ; Hering MA; James SF; Sun MM; Doronina SO; Siadak AW; Senter PD; Wahl AF
Clin Cancer Res; 2005 Jan; 11(2 Pt 1):843-52. PubMed ID: 15701875
[TBL] [Abstract][Full Text] [Related]
16. Novel auristatin E-based albumin-binding prodrugs with superior anticancer efficacy in vivo compared to the parent compound.
Pes L; Koester SD; Magnusson JP; Chercheja S; Medda F; Abu Ajaj K; Rognan D; Daum S; Nollmann FI; Garcia Fernandez J; Perez Galan P; Walter HK; Warnecke A; Kratz F
J Control Release; 2019 Feb; 296():81-92. PubMed ID: 30639692
[TBL] [Abstract][Full Text] [Related]
17. Effects of drug loading on the antitumor activity of a monoclonal antibody drug conjugate.
Hamblett KJ; Senter PD; Chace DF; Sun MM; Lenox J; Cerveny CG; Kissler KM; Bernhardt SX; Kopcha AK; Zabinski RF; Meyer DL; Francisco JA
Clin Cancer Res; 2004 Oct; 10(20):7063-70. PubMed ID: 15501986
[TBL] [Abstract][Full Text] [Related]
18. A humanized trivalent Nectin-4-targeting nanobody drug conjugate displays potent antitumor activity in gastric cancer.
Wu Y; Zhu M; Sun B; Chen Y; Huang Y; Gai J; Li G; Li Y; Wan Y; Ma L
J Nanobiotechnology; 2024 May; 22(1):256. PubMed ID: 38755613
[TBL] [Abstract][Full Text] [Related]
19. Radiation Cleaved Drug-Conjugate Linkers Enable Local Payload Release.
Quintana JM; Arboleda D; Hu H; Scott E; Luthria G; Pai S; Parangi S; Weissleder R; Miller MA
Bioconjug Chem; 2022 Aug; 33(8):1474-1484. PubMed ID: 35833631
[TBL] [Abstract][Full Text] [Related]
20. Development of a Novel EGFR-Targeting Antibody-Drug Conjugate for Pancreatic Cancer Therapy.
Li Z; Wang M; Yao X; Luo W; Qu Y; Yu D; Li X; Fang J; Huang C
Target Oncol; 2019 Feb; 14(1):93-105. PubMed ID: 30635821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
